File(s) under permanent embargo
Immune checkpoints in targeted-immunotherapy of pancreatic cancer: new hope for clinical development
journal contribution
posted on 2023-05-23, 00:01 authored by Kiaie, SH, Sanaei, MJ, Heshmati, M, Asadzadeh, Z, Iman AzimiIman Azimi, Hadidi, S, Jafari, R, Baradaran, BImmunotherapy has been recently considered as a promising alternative for cancer treatment. Indeed, targeting of immune checkpoint (ICP) strategies have shown significant success in human malignancies. However, despite remarkable success of cancer immunotherapy in pancreatic cancer (PCa), many of the developed immunotherapy methods show poor therapeutic outcomes in PCa with no or few effective treatment options thus far. In this process, immunosuppression in the tumor microenvironment (TME) is found to be the main obstacle to the effectiveness of antitumor immune response induced by an immunotherapy method. In this paper, the latest findings on the ICPs, which mediate immunosuppression in the TME have been reviewed. In addition, different approaches for targeting ICPs in the TME of PCa have been discussed. This review has also synopsized the cutting-edge advances in the latest studies to clinical applications of ICP-targeted therapy in PCa.
History
Publication title
Acta Pharmaceutica Sinica BISSN
2211-3835Department/School
School of Pharmacy and PharmacologyPublisher
Zhongguo Yixue Kexueyuan Yaowu Yanjiusuo,Institute of Materia Medica (IMM)Place of publication
ChinaRepository Status
- Restricted